Global Information
회사소개 | 문의 | 비교리스트

정신분열증 : 주요 27개국 시장 예측

Epiomic Epidemiology Series: Schizophrenia Forecast in 27 Major Markets 2018-2028

리서치사 Black Swan Analysis
발행일 2019년 03월 상품 코드 626781
페이지 정보 영문 108 Pages
가격
US $ 5,800 ₩ 7,188,000 PDF by E-mail (Single User License)
US $ 8,700 ₩ 10,782,000 PDF by E-mail (Site License/Up to 5 Users)
US $ 10,400 ₩ 12,889,000 PDF by E-mail (Corporate License)


정신분열증 : 주요 27개국 시장 예측 Epiomic Epidemiology Series: Schizophrenia Forecast in 27 Major Markets 2018-2028
발행일 : 2019년 03월 페이지 정보 : 영문 108 Pages

세계 주요 27개국의 정신분열증(Schizophrenia) 이환 상황을 조사했으며, 유병자수 추이와 예측, 국가·연령층·성별·질환별 분석, 질환 개요, 위험인자, 질환 진단과 예후, 주요 증상과 동반질환 등의 정보를 정리했습니다.

조사 대상국

  • 미국
  • 캐나다
  • 프랑스
  • 독일
  • 이탈리아
  • 스페인
  • 영국
  • 폴란드
  • 네덜란드
  • 벨기에
  • 노르웨이
  • 스웨덴
  • 핀란드
  • 덴마크
  • 오스트리아
  • 스위스
  • 아일랜드
  • 러시아
  • 터키
  • 일본
  • 중국
  • 한국
  • 인도
  • 호주
  • 브라질
  • 멕시코
  • 아르헨티나

본 보고서에서 다룬 정신분열증의 주요 증상과 동반질환

  • 정서적 둔마(Affective flattening)
  • 무관심
  • 주의력 결핍
  • 무감정
  • 의욕 저하
  • 언어빈곤(Poverty of speech)
  • 사회적 위축(Social withdrawal)
  • 망상
  • 환각
  • 인지장애
LSH 19.04.03

이 페이지에 게재되어 있는 내용은 최신판과 약간 차이가 있을 수 있으므로 영문목차를 함께 참조하여 주시기 바랍니다. 기타 자세한 사항은 문의 바랍니다.

Schizophrenia is a mental illness characterised by psychosis, apathy and withdrawal, as well as cognitive impairment. It usually develops between late adolescence and young adult age, and although no significant differences in the prevalence of schizophrenia have been observed between men and women overall, there are differences in age at onset and tendency to present certain symptoms. Schizophrenia constitutes a significant burden to social and professional life, with more severe forms also causing basic self-care problems. With its life-long duration, it is one of the leading causes of long-term disability worldwide.

This report provides the current prevalent population for Schizophrenia across 27 Major Markets (USA, Canada, France, Germany, Italy, Spain, UK, Poland, Netherlands, Belgium, Norway, Sweden, Finland, Denmark, Austria, Switzerland, Ireland, Russia, Turkey, Japan, China, South Korea, India, Australia, Brazil, Mexico, Argentina) split by gender and 5-year age cohort. In addition to the current prevalence, the report provides an overview of the risk factors, diagnosis and prognosis of the disease, along with specific variations by geography and ethnicity.

Providing a value-added level of insight from the analysis team at Black Swan, Schizophrenia patients grouped by symptoms and co-morbidities have been quantified and presented alongside the overall prevalence figures. These sub-populations within the main disease are also included at a country level across the 10-year forecast snapshot.

Main symptoms and co-morbidities of Schizophrenia include:

  • Affective flattening
  • Apathy
  • Attentional impairment
  • Emotional withdrawal
  • Poor motivation
  • Poverty of speech
  • Social withdrawal
  • Delusions
  • Hallucinations
  • Cognitive Impairment

This report is built using data and information sourced from the proprietary Epiomic patient segmentation database. To generate accurate patient population estimates, the Epiomic database utilises a combination of several world-class sources that deliver the most up-to-date information form patient registries, clinical trials and epidemiology studies. All of the sources used to generate the data and analysis have been identified in the report.

Reason to buy:

  • Ability to quantify patient populations in global Schizophrenia market to target the development of future products, pricing strategies and launch plans.
  • Further insight into the prevalence of the subdivided types of Schizophrenia and identification of patient segments with high potential.
  • Delivery of more accurate information for clinical trials in study sizing and realistic patient recruitment for various countries.
  • Identification of Schizophrenia patient sub-populations that require treatment.
  • Better understanding of the specific markets that have the largest number of Schizophrenia patients.

Country Coverage

Back to Top
전화 문의
F A Q